NEU1 and pancreatic ductal adenocarcinoma: However, in another study, miR-125b expression was shown to be increased in a cell line model of gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) in the contexts of EMT and chemoresistance, which lends support to the potential antitumor activity of NEU1 as evidenced by the attenuated expression of NEU-1 in the model [146].